Cetuximab was found to inhibit the Nrf2/HO-1 signaling pathway in KRAS mutant CRC, promoting RSL3-induced ferroptosis and overcoming drug resistance in KRAS-mutant CRC [71]. This evidence concerns the gene KRAS and colorectal carcinoma.